The Latest Breaking News on Pharma

Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants

Swiss eye care company Alcon (ALC) recently announced that it would acquire Aerie Pharmaceuticals (AERI) for $770 million. The deal is expected to help bolster ALC’s expansion into the ophthalmic pharmaceutical space. So, will it be wise to invest in the stock now? Read on to learn our view….

Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine

‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

The lawsuit seeks unspecified monetary damages for patent infringement.

Australian police said on Friday it had seized some A$1.6 billion ($1.1 billion) worth of crystal meth, also known as 'ice', concealed within marble stones in several sea freight containers, in what it said was the biggest ever haul of the drug in the country.

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…